Kanno Toru, Shibasaki Noboru, Tsuji Yutaka, Taki Yoji, Takeuchi Hideo
Department of Urology, Toyooka Hospital.
Hinyokika Kiyo. 2004 Aug;50(8):521-4.
Six patients with hormone refractory prostate cancer were orally administered 560 mg of Estramustine daily in 2 equally divided doses for four or five days. In addition 70 mg/m2 of Docetaxel was infused through intravenous drip from day 1, decreasing to 40-60 mg/m2 if any side effects such as bone marrow depression were observed. One cycle was three weeks in hospital and one month after discharge. Patients were treated until progression or the development of treatment-limiting toxicity. In five of the six patients (83.3%), serum prostate specific antigen (PSA) was decreased by more than 50%. Currently, this therapy is ongoing in four outpatients. A side effect of leucopenia (grade 2 or 3) was observed in all patients. Granulocyte-colony stimulating factor (G-CSF) formulation was given as treatment. One case was withdrawn due to loss of appetite after one cycle. This therapy is considered to be effective against hormone refractory prostate cancer. However, further examination is needed about dosage and dosing regimen of Estramustine and Docetaxel.
6例激素难治性前列腺癌患者每日口服560毫克雌莫司汀，分2次等量服用，共服用4至5天。此外，从第1天开始，通过静脉滴注给予70毫克/平方米的多西他赛，如果观察到任何副作用，如骨髓抑制，则减至40 - 60毫克/平方米。一个周期为住院3周，出院后1个月。患者接受治疗直至病情进展或出现治疗限制毒性。6例患者中有5例（83.3%）血清前列腺特异性抗原（PSA）下降超过50%。目前，4名门诊患者正在接受这种治疗。所有患者均观察到白细胞减少（2级或3级）的副作用，给予粒细胞集落刺激因子（G-CSF）制剂进行治疗。1例患者在一个周期后因食欲不振而退出。这种治疗被认为对激素难治性前列腺癌有效。然而，关于雌莫司汀和多西他赛的剂量和给药方案还需要进一步研究。
